Patent · US Expired

Indolinone derivatives

US7223783B2 · kind B2 · utility

0Cited by
3References
17Claims
0Family size

Assignee

Inventors

Key dates

Filing dateFeb 21, 2006
Grant dateMay 29, 2007
Priority date
Expiry dateFeb 21, 2026

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P43/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Compounds of formula (I)in which R1, R2, R3 and R4 have the meanings given in the specification, are receptor tyrosine kinase inhibitors useful in the treatment of proliferative disorders, such as cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.